A number of other analysts have also recently weighed in on ALBO. ValuEngine cut Albireo Pharma from a “strong-buy” rating to a “buy” rating in a research report on Thursday, April 18th. Zacks Investment Research upgraded Albireo Pharma from a “sell” rating to a “hold” rating in a research note on Tuesday, May 14th. William Blair reiterated an “outperform” rating on shares of Albireo Pharma in a research note on Thursday, May 9th. Cowen reiterated a “buy” rating on shares of Albireo Pharma in a research note on Wednesday, April 17th. Finally, Wedbush set a $69.00 price objective on Albireo Pharma and gave the stock a “buy” rating in a research note on Sunday, March 10th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $54.25.
Shares of NASDAQ:ALBO opened at $32.72 on Tuesday. Albireo Pharma has a fifty-two week low of $19.10 and a fifty-two week high of $38.69. The stock has a market capitalization of $394.91 million, a price-to-earnings ratio of -8.30 and a beta of 1.66.
Albireo Pharma (NASDAQ:ALBO) last announced its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.37) by ($0.02). Albireo Pharma had a negative return on equity of 47.03% and a negative net margin of 2,900.81%. The company had revenue of $0.57 million during the quarter, compared to analyst estimates of $1.20 million. Sell-side analysts expect that Albireo Pharma will post -5.99 EPS for the current fiscal year.
Institutional investors have recently bought and sold shares of the company. Metropolitan Life Insurance Co. NY increased its stake in shares of Albireo Pharma by 356.5% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 3,328 shares of the biopharmaceutical company’s stock worth $82,000 after purchasing an additional 2,599 shares during the period. Bank of America Corp DE increased its stake in shares of Albireo Pharma by 87.6% in the fourth quarter. Bank of America Corp DE now owns 6,469 shares of the biopharmaceutical company’s stock worth $159,000 after purchasing an additional 3,020 shares during the period. M&T Bank Corp bought a new position in shares of Albireo Pharma in the first quarter worth about $201,000. Rhumbline Advisers increased its stake in shares of Albireo Pharma by 40.2% in the fourth quarter. Rhumbline Advisers now owns 13,056 shares of the biopharmaceutical company’s stock worth $320,000 after purchasing an additional 3,743 shares during the period. Finally, State of Wisconsin Investment Board increased its stake in shares of Albireo Pharma by 29.5% in the first quarter. State of Wisconsin Investment Board now owns 12,300 shares of the biopharmaceutical company’s stock worth $396,000 after purchasing an additional 2,800 shares during the period. Institutional investors and hedge funds own 70.41% of the company’s stock.
Albireo Pharma Company Profile
Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.
Featured Article: Front-End Load
Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.